Instituto de Olhos de Goiania

Quick facts

Marketed products

• Aflibercept and ranibizumab · Ophthalmology
  Aflibercept and ranibizumab are anti-VEGF agents that inhibit vascular endothelial growth factor to reduce abnormal blood vessel growth and leakage in the eye.
• Ranibizumab and Aflibercept · Ophthalmology
  Ranibizumab and aflibercept are anti-VEGF agents that inhibit vascular endothelial growth factor to reduce abnormal blood vessel growth and leakage in the retina.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Instituto de Olhos de Goiania portfolio CI brief
• Instituto de Olhos de Goiania pipeline updates RSS